Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until June, 2020.

  1. Correction of Splicing Defects in Cystic Fibrosis with Peptide-Oligonucleotide Conjugates and Small Molecule Enhancing Compounds

    SBC: Initos Pharmaceuticals LLC            Topic: NCATS

    ABSTRACT The pathogenesis of Cystic FibrosisCFis caused by mutations in the gene for CFTRa cAMP activated chloride channel that regulates salt and water transport in epithelial tissuesespecially those in the airwaysRecent progress has resulted in small molecule therapeutic agents that partially correct defects in the CFTR protein due to certain mutationsHoweverin a substantial fraction of CF patie ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a predictive moderate throughput assay to screen novel Designer Proline-rich antimicrobial peptide Chaperone protein inhibitors (DPCs) against multi-drug resistant pathogen

    SBC: Arrevus, Inc.            Topic: NIAID

    Multi drug resistantMDRbacterial infections represent a significant threat to public healthIt is estimated that the impact of antibiotic resistance will continue to grow resulting in a global economic burden of $trillion and causingmillion deaths annuallyMany of the therapeutics currently under development represent traditional antibiotic approaches or next generation antibiotics that will likely ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Novel and potent SHIP1 inhibitors for improving hematologic recovery following myelosuppressive therapies

    SBC: Alterna Therapeutics, Inc.            Topic: NHLBI

    ABSTRACT Despite recent advances in targeting cancer cellschemotherapy remains a mainstay of oncologyextending survival and providing cures for many types of cancerHoweverchemotherapy that ablates or suppresses bone marrow cells can be debilitating even when combined with autologous hematopoietic stem cell transplantationHSCTThe treatment causes severe side effects such as anemianeutropenia and th ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Automated CRISPR Screening Using the CellRaft Technology

    SBC: Cell Microsystems, Inc.            Topic: 400

    Project SummaryGenome wide functional genetics has been recently made possible by pooled library based CRISPR Casgene editing technologyBy randomly knocking out thousands of geneslarge scale screens can be conducted for functional geneticsdrug sensitivity and other phenotypesCurrently howeverthis forward genetic approach is largely relegated to live dead screens in mammalian cellsImproving the sop ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Mobile Peer Support for Opioid Use Disorders: Refinement of an Innovative Machine Learning Tool

    SBC: Beacon Tech Inc.            Topic: R41

    PROJECT SUMMARY This proposal develops a novelartificial intelligenceAIenabledmobile treatment delivery method that fulfills the need for a robustsecuretechnology based peer support platform to support patients with opioid use disordersOUDsThe majority of individuals with OUDs in the United States do not receive any formal substance use treatmentand growing evidence suggests that many OUD patients ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Developing a Small Peptide to Control Autoimmune Inflammation In Type 1 Diabetes

    SBC: Op-T-Mune, Inc            Topic: NIAID

    TypeDiabetesT Daffects an ever growing populationWhile this disease typically has been associated with juvenilesthe disease in adult populations is rapidly increasingThe defining clinical component is insulin losswhich occurs because of sustained inflammation in the isletsAt present there is no means to prevent or reverse insulin lossA major inflammatory pathway in T D that contributes to insulin ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Automated point-of-care identification of innocent Still's murmur in children

    SBC: AUSCULTECH DX LLC            Topic: NHLBI

    PROJECT SUMMARY The overall goal of the proposed research and technology transfer effort is to develop a low costpoint of caremobile device based technology for automated identification of Stillandapos s murmurthe most common innocentbenign and harmlessheart murmur of childhoodThis novel technology could reduce the current rate of over half a million children unnecessarily referred to pediatric ca ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Personalized Neural Stem Cell Therapy for Cancer

    SBC: Falcon Therapeutics, Inc.            Topic: NCATS

    PROJECT SUMMARY GlioblastomaGBMis an intractable cancer with an average survival time oftomonthsTreatment options are limited by the infiltration of tumor cells into healthy tissue and the difficulty of delivering effective chemotherapeutics across the blood brain barrierbut engineered neural stem cellsNSCshold great promise as GBM therapies because they selectively migrate to tumor cells and can ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Oxidation-resistant Anti-protease Therapy

    SBC: LEXEO Therapeutics LLC            Topic: NHLBI

    AbstractLEXEO TherapeuticsLLCis an early stage biotechnology company focused on using gene therapy technologies to protect vulnerable organs from oxidant stressLEXthest LEXEO productis ast in classnext generation gene therapy treatment for alphaantitrypsinAATdeficiencyan autosomal recessive hereditary disorder associated with low serum levels of AATAATSERPINAakDa serine antiprotease produced by th ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Use of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating antibiotic resistant pneumonia

    SBC: Arrevus, Inc.            Topic: NIAID

    Project SummaryInfectious disease is the third leading cause of death in the United Statesand hospital acquired infectionsHAIsin particular affectmillion patients annuallyThe most common type of HAI is pneumoniaoften caused by multi drug resistantMDRpathogens such as Staphylococcus aureusPseudomonas aeruginosaKlebsiella pneumoniaeEscherichia coliand Acinetobacter baumanniiRates of antibiotic resis ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government